Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2019 / N 2

Амантадин при болезни Гентингтона: pros and cons
С.А. Клюшников, С.Н. Иллариошкин, Ю.А. Селивёрстов

References

1. Baig SS, Strong M, Quarrell OWJ. The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodenenerative Disease Management 2016 Aug;6(4):331-43.
2. Huntington G. On chorea. Medical and Surgical Reporter (Philadelphia) 1872;26:317-21.
3. Illarioshkin SN, Klyushnikov SA, Seliverstov YuA. Huntington’s disease. Monograph. Moscow: Atmosphera; 2018. 472 p. (In Russian).
4. Hayden MR. Huntington’s chorea. Berlin, Heidelberg, New York: Springer-Verlag; 1981. 192 p.
5. Folstein SE. Huntington’s disease: a disorder of families. Baltimore: Johns Hopkins University Press; 1989. 251 p.
6. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington’s disease. The Lancet. Neurology 2009 Aug;8(8):765-74.
7. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington’s disease. Current Topics in Developmental Biology 2006;75:25-71.
8. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993 Mar;72(6):971-83.
9. Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. American Journal of Human Genetics 1999 Feb;64(2):339-45.
10. Harding RJ, Tong YF. Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacologica Sinica 2018 May;39(5):754-69.
11. Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. The Journal of Biological Chemistry 2011 Dec;286(52):44512-20.
12. Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochimica et Biophysica Acta 2012 Feb;1822(2):101-10.
13. Skotte NH, Andersen JV, Santos A, Aldana B, Willert CW, Nørremølle A, Waagepetersen HS, Nielsen ML. Integrative сharacterization of the R6/2 mouse model of Huntington’s disease reveals dysfunctional astrocyte metabolism. Cell Reports 2018 May;23(7):2211-24.
14. Mestre TA, Sampaio C. Huntington disease: linking pathogenesis to the development of experimental therapeutic. Current Neurology and Neuroscience Reports 2017 Feb;17(2):18.
15. Illarioshkin SN, Klyushnikov SA, Vigont VA, Seliverstov YuA, Kaznacheyeva EV. Molecular pathogenesis in Huntington’s disease. Biochemistry (Moscow) 2018 Sep;83(9):1030-9.
16. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurology 1995 Sep;38(3):357-66.
17. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacology & Therapeutics 1999 Mar;81(3):163-221.
18. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004 Jan;1:101-10.
19. Illarioshkin SN, Klyushnikov SA, Brylev LV, Fedin PA, Markova ED, Ivanova-Smolenskaya IA. Preventive neuroprotection in neurodegenerative diseases: glutamate receptor antagonists administration (review of literature and own experience). The Neurological Journal 2006;11(5):47-54 (In Russian).
20. Budd SL, Tenneti L, Lishnak T, Lipton SA. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proceedings of the National Academy of Sciences of the USA 2000 May;97(11):6161-6.
21. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976 Oct;263(5577):517-9.
22. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. The Journal of Neuroscience 1991 Jun;11(6):1649-59.
23. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. Journal of Neurochemistry 1999 May;72(5):1890-8.
24. Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, Raymond LA. Mutant huntingtin enhances excitotoxic cell death. Molcular and Cellular of Neurosciences 2001 Jan;17(1):41-53.
25. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 2002 Mar;33(6):849-60.
26. Li JY, Plomann M, Brundin P. Huntington’s disease: a synaptopathy? Trends in Molecular Medicine 2003 Oct;9(10):414-20.
27. Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology 2004 Nov;92(5):2738-46.
28. Cersósimo MG, Micheli FE. Antiglutamatergic drugs in the treatment of Parkinson’s disease. In: Handbook of clinical neurology. Koller C, Melamed E, editors. V. 84. Parkinson’s disease and related disorders. Part II. New York: Elsevier; 2007: 127-36.
29. Elahi B, Phielipp N, Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Canadian Journal of Neurological Sciences 2012 Jul;39(4):465-72.
30. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995 Jul;34(7):713-21.
31. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 2007;21(8):677-92.
32. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Movement Disordres 2010 Jul;25(10):1357-63.
33. Ilzenberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi C, Rossi C, Klein C, Rabey JM. Association between amantadine and the onset of dementia in Parkinson’s disease. Movement Disorders 2006 Sep;21(9):1375-9.
34. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment as an independent predictor of improved survival in Parkinson’s disease. Neurology 1996 Jun;46(6):1551-6.
35. Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012 Aug;79(6):597-603.
36. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002 Sep;59(5):694-9.
37. Lucetti C, Del Dotto P, Gambaccini G, Dell’ Agnello G, Bernardini S, Rossi G, Murri L, Bonuccelli U. IV amantadine improves chorea in Huntington’s disease: an acute randomized, controlled study. Neurology 2003 Jun;60(12):1995-7.
38. O’Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Archives of Neurology 2003 Jul;60(7):996-8.
39. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington’s disease. The Cochrane Database of Systematic Reviews 2009;(3):CD006456.
40. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology 2010 Nov-Dec;33(6):271-5.
41. Fedorova NV,Vetokhina TN. Neuroleptic extrapyramidal disorders. In: Parkinson’s disease and movement disorders. Guidelines for physicians. Proceedings of the 2nd National Congress “Parkinson’s Disease and Movement Disorders” (with international participation). Illariushkin SN, Levin OS, editors. Moscow, 2011: 275-80 (In Russian).
42. Botez MI, Botez-Marquard T, Elie R, Le Marec N, Pedraza OL, Lalonde R. Amantadine hydrochloride treatment in olivopontocerebellar atrophy: a long-term follow-up study. European Neurology 1999;41(4):212-5.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]